AN OPPORTUNITY TO EMBRACE THE LATEST SCIENCE. ELEVATE OUR STANDARDS. AND USHER IN A NEW ERA OF EXCELLENCE.
Organogenesis is the premier line of advanced healing solutions.
At Extremity Care we offer a diverse portfolio of cell and tissue products including placental allografts, xenografts, acellular dermis, adipose tissue, and conservative wound care products. We focus on technologies that support the repair, reconstruction, replacement, or supplementation of the patient’s own tissue.
We provide compliant just-in-time handling of human tissue to and from the clinic with our careLOG™ shipping logistic. careLOG™ is a patient-specific Allograft shipping logistic. The package contains the tissue and all billing-related documents needed to request reimbursement.
Through our dedicated lab and AATB accredited tissue bank we are at the forefront of cell and tissue engineering and strive to be good stewards of the precious gift of tissue donation.
Convatec has the first and only FDA-cleared placental medical devices for chronic wounds, surgical wounds, and burns with its innovative InnovaMatrix® technology platform -- now available in powder form and a variety of membrane sizes. For more information, visit www.innovamatrix.com.
Integra LifeSciences (Integra) was founded in 1989 based on a vision to expand access to promising technology that enables the body to regenerate damaged or diseased tissue. Grounded on this vision, the company revolutionized the field of regenerative medicine and has since grown to be a leading global provider of neurosurgical solutions, regenerative technologies, and surgical instrumentation Our regenerative tissue technologies include products that address soft tissue, peripheral nerve and tendon repairs and are used for the treatment of acute and chronic wounds, burns, as well as for plastic and reconstructive surgery.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. Alongside our customers we will not settle until we have solved the challenges of preventing and healing wounds, because they hold back too many lives.
Headquartered in Auckland, New Zealand, Aroa Biosurgery is a global medical device company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.
The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.
Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people across New Zealand and North America. To date, more than 6 million AROA ECM™ devices have been used in treating patients worldwide.
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA-registered and AATB-accredited site in Pompano Beach, Florida.
Kerecis is pioneering the use of fish skin and fatty acids in the globally expanding cellular-therapy and regenerative-medicine markets. The fatty-acid-rich products from the company’s patented technologies protect the body’s own tissues and enable the body to regenerate tissues.
Developed and manufactured in Isafjordur, Iceland, Kerecis medical products are authorized for sale in Europe, the United States. and several other jurisdictions for human-tissue repair. Thousands of patients are treated annually with our technology. And we are broadening our product line to address many more types of soft-tissue damage.
Merakris Therapeutics, founded in 2016, is at the forefront of scientific advancement in regenerative medicine. Dedicated to championing a precision medicine approach to wound care, Merakris seeks to improve global patient care and outcomes with cell-free regenerative therapies. The company's flagship Dermacyte Amniotic Wound Care Matrix provides a protective barrier to cover wounds and soft tissue to facilitate faster and more effective healing of various wound types. Dermacyte Liquid, a subcutaneous cell-free human amniotic fluid injection for complex wound healing, is currently in Phase 2 clinical trials. The company also is investigating other novel biomedical solutions that promote wound healing and tissue regeneration.
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
MTF Biologics Wound Care is a division of MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. The Wound Care Division is dedicated to developing highly advanced, safe, clinically based and cost-effective wound care solutions that work in concert with the body’s natural healing process.
OCM™ is the first of it’s kind, HCP administered, drug-device combination product delivering comprehensive therapy to address all phases of wound healing: reduce biofilm impact, decrease inflammation, increase proliferation, and support remodelling. Rich in cold water fish peptides and other pharmaceutical grade components that are natural antimicrobials and non-cytotoxic, this novel treatment provides safe and effective wound management with the ability to use day 1.
ProgenaCare™ is a purpose-driven medical device company leveraging cutting-edge advances in materials science to provide effective, affordable advanced wound care solutions for patients across the socioeconomic spectrum and around the globe. ProgenaMatrix®, the first and only human keratin matrix for wound care, is built on our proprietary human keratin platform. revyve™ Antimicrobial Wound Gel is an advanced hydrogel with a thermo-gelling surfactant and long-lasting broad spectrum antimicrobial activity. From fresh start to finish, ProgenaCare is here to help you heal your patients.
Reprise Biomedical is focused on the development and commercialization of biological medical devices that offer advanced solutions for wound healing. In 2019, Reprise took ownership of two products, under a proprietary perfusion decellularization technology license from the University of Minnesota, MiroDerm biologic wound matrix for advanced wound management and MiroFlex biologic matrix for soft tissue reinforcement. Reprise is committed to delivering novel solutions which address unmet surgical needs for advanced wound care. Our transformational, Miro3D wound matrix, is an example of that commitment. Miro3D broadens our wound management portfolio by offering a unique three-dimensional solution for deep and tunneling wounds.
Urgo provides medical devices and products to hospitals, nursing homes and home health agencies – and the patients they treat. Our focused portfolio of products establishes proven protocols for the care and management of wounds, skin, and skin breakdown.
The Association for the Advancement of Wound Care (AAWC) is the largest, non-profit, interdisciplinary wound care organisation in the US, focused on education, public policy and the application of evidence-based wound care practice. Conceived in 1995, the mission of the AAWC is to advance the care of people with and at risk of wounds.
The American College of Clinical Wound Specialists (ACCWS) is dedicated to the advocacy, ongoing wound care education, and support of credentialed wound care providers of all disciplines. Our members strive to improve the public’s health by practicing and encouraging evidence-based wound care management to promote healing.
The American Professional Wound Care Association® (APWCA) is a non-profit medical association welcoming medical providers from all disciplines involved in prevention and treatment of difficult wounds. Through a synergy of disciplines, APWCA has been a worldwide leader in clinician advocacy and education for the prevention and treatment of acute and chronic wounds since 2001. This association provides an informational and educational forum for healthcare providers, while promoting excellence in wound healing and patient advocacy.
The Academy of Physicians in Wound Healing (APWH) is an organisation that provides information and support in three subject areas: clinical and operations-focused education, compensation advocacy, and legislative action on healthcare issues. Additionally, the organisation provides this information specifically to providers that are responsible for diagnosis and management of patient care.
SmartTRAK is the MedTech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product, and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.